Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: H igher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
Diabetes Obesity and Metabolism2017Vol. 19(7), pp. 953–961
Citations Over TimeTop 10% of 2017 papers
Carlos Alatorre, Laura Fernández Landó, Maria Yu, Katelyn Brown, Leslie Montejano, Paul Juneau, Reema Mody, Ralph Swindle
Abstract
Dulaglutide initiators had significantly higher adherence, were more persistent, and had lower discontinuation rates compared with initiators of exenatide once weekly or liraglutide during the 6-month follow-up period.
Related Papers
- → Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results(2009)127 cited
- → Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes(2017)71 cited
- → Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials(2016)22 cited
- → A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK(2020)8 cited
- Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.(2017)